Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CECR2 | Q9BXF3 | 7/20 | 0.52 |
| ▸ | TAF1 | P21675 | 5/20 | 0.52 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.52 |
| ▸ | BRD4 | O60885 | 8/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17754104 | 0.89 | CECR2 (0.54) | CECR2TAF1BRD9BRD4KMT2A | |
| SCHEMBL19639705 | 0.89 | CECR2 (0.54) | CECR2TAF1BRD9BRD4KMT2A | |
| SCHEMBL17748995 | 0.89 | CECR2 (0.54) | CECR2TAF1BRD9BRD4KMT2A | |
| SCHEMBL17754172 | 0.87 | BRD4 (0.52) | CECR2TAF1BRD9BRD4ALDH1A1 | |
| SCHEMBL17753665 | 0.87 | TAF1 (0.52) | CECR2TAF1BRD9BRD4RIPK1 | |
| SCHEMBL19658980 | 0.79 | BRD9 (0.35) | CECR2TAF1BRD9BRD4RIPK1 | |
| SCHEMBL17753661 | 0.79 | TSHR (0.53) | CECR2TAF1BRD9BRD4KMT2A | |
| SCHEMBL17753679 | 0.78 | CECR2 (0.50) | CECR2TAF1BRD9BRD4ATAD2 | |
| SCHEMBL17753685 | 0.78 | CECR2 (0.50) | CECR2TAF1BRD9BRD4ATAD2 | |
| SCHEMBL17753771 | 0.78 | CECR2 (0.55) | CECR2TAF1BRD9BRD4ATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | CECR2 184/4885TAF1 439/4885BRD9 16/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CECR2 184/4885TAF1 439/4885BRD9 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.